Medartis Holding AG

SWX:MED Stock Report

Market Cap: CHF 652.6m

Medartis Holding Valuation

Is MED undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MED when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: MED (CHF48) is trading above our estimate of fair value (CHF15.09)

Significantly Below Fair Value: MED is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MED?

Key metric: As MED is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MED. This is calculated by dividing MED's market cap by their current revenue.
What is MED's PS Ratio?
PS Ratio3x
SalesCHF 220.28m
Market CapCHF 652.59m

Price to Sales Ratio vs Peers

How does MED's PS Ratio compare to its peers?

The above table shows the PS ratio for MED vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.3x
MEDX medmix
0.8x4.0%CHF 374.4m
METN Metall Zug
1.1x-26.8%CHF 510.8m
MOVE Medacta Group
4.4x11.9%CHF 2.2b
STMN Straumann Holding
6.9x8.6%CHF 17.6b
MED Medartis Holding
3x13.7%CHF 652.6m

Price-To-Sales vs Peers: MED is good value based on its Price-To-Sales Ratio (3x) compared to the peer average (3.3x).

Price to Sales Ratio vs Industry

How does MED's PS Ratio compare vs other companies in the European Medical Equipment Industry?

33 CompaniesPrice / SalesEstimated GrowthMarket Cap
MED 3.0xIndustry Avg. 3.4xNo. of Companies33PS03.26.49.612.816+
33 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: MED is good value based on its Price-To-Sales Ratio (3x) compared to the European Medical Equipment industry average (3.4x).

Price to Sales Ratio vs Fair Ratio

What is MED's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MED PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3x
Fair PS Ratio5.7x

Price-To-Sales vs Fair Ratio: MED is good value based on its Price-To-Sales Ratio (3x) compared to the estimated Fair Price-To-Sales Ratio (5.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MED forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 48.00
CHF 98.20
+104.6%
10.0%CHF 110.00CHF 85.40n/a4
Nov ’25CHF 56.20
CHF 98.20
+74.7%
10.0%CHF 110.00CHF 85.40n/a4
Oct ’25CHF 57.20
CHF 98.20
+71.7%
10.0%CHF 110.00CHF 85.40n/a4
Sep ’25CHF 63.50
CHF 98.20
+54.6%
10.0%CHF 110.00CHF 85.40n/a4
Aug ’25CHF 75.00
CHF 98.98
+32.0%
9.5%CHF 110.00CHF 85.40n/a4
Jul ’25CHF 68.40
CHF 98.98
+44.7%
9.5%CHF 110.00CHF 85.40n/a4
Jun ’25CHF 76.50
CHF 98.98
+29.4%
9.5%CHF 110.00CHF 85.40n/a4
May ’25CHF 80.20
CHF 98.98
+23.4%
9.5%CHF 110.00CHF 85.40n/a4
Apr ’25CHF 89.40
CHF 98.85
+10.6%
9.7%CHF 110.00CHF 84.90n/a4
Mar ’25CHF 72.70
CHF 96.78
+33.1%
11.7%CHF 110.00CHF 81.80n/a4
Feb ’25CHF 73.90
CHF 101.77
+37.7%
8.2%CHF 110.00CHF 90.30n/a3
Jan ’25CHF 84.00
CHF 101.77
+21.2%
8.2%CHF 110.00CHF 90.30n/a3
Dec ’24CHF 73.20
CHF 101.77
+39.0%
8.2%CHF 110.00CHF 90.30n/a3
Nov ’24CHF 71.40
CHF 101.77
+42.5%
8.2%CHF 110.00CHF 90.30CHF 56.203
Oct ’24CHF 84.10
CHF 132.65
+57.7%
31.9%CHF 175.00CHF 90.30CHF 57.202
Sep ’24CHF 88.50
CHF 113.43
+28.2%
38.8%CHF 175.00CHF 75.00CHF 63.503
Aug ’24CHF 81.00
CHF 110.13
+36.0%
43.0%CHF 175.00CHF 63.00CHF 75.003
Jul ’24CHF 76.70
CHF 110.13
+43.6%
43.0%CHF 175.00CHF 63.00CHF 68.403
Jun ’24CHF 74.30
CHF 119.00
+60.2%
47.1%CHF 175.00CHF 63.00CHF 76.502
May ’24CHF 74.10
CHF 119.00
+60.6%
47.1%CHF 175.00CHF 63.00CHF 80.202
Apr ’24CHF 71.40
CHF 119.00
+66.7%
47.1%CHF 175.00CHF 63.00CHF 89.402
Mar ’24CHF 70.40
CHF 126.50
+79.7%
38.3%CHF 175.00CHF 78.00CHF 72.702
Feb ’24CHF 76.50
CHF 126.50
+65.4%
38.3%CHF 175.00CHF 78.00CHF 73.902
Jan ’24CHF 82.00
CHF 126.50
+54.3%
38.3%CHF 175.00CHF 78.00CHF 84.002
Dec ’23CHF 90.40
CHF 126.50
+39.9%
38.3%CHF 175.00CHF 78.00CHF 73.202
Nov ’23CHF 77.80
CHF 124.00
+59.4%
32.1%CHF 175.00CHF 78.00CHF 71.403

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Siemens Healthineers

€56.0b

Through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers worldwide.

SHL

€46.32

7D

-1.4%

1Y

n/a

Becton Dickinson

US$66.7b

Develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.

912061

US$238.02

7D

0%

1Y

-2.2%

Abbott Laboratories

US$201.0b

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.

ABT

US$93.50

7D

0%

1Y

2.7%